SCHEMBL4192099

SCHEMBL4192099

O=C([O-])C[N+]1(CCO)CCOCC1

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190131 0.83
SCHEMBL17338057 0.82
SCHEMBL4907261 0.79 SMN1; SMN2 (0.36) ALDH1A1
SCHEMBL8370925 0.78 MEN1 (0.31) MEN1ALDH1A1KMT2A
Hydrochloric Acid SCHEMBL30804526 0.77 SMN1; SMN2 (0.35) ALDH1A1
SCHEMBL11801179 0.74 SMN1; SMN2 (0.30)
SCHEMBL4905084 0.71 CTDSP1 (0.35)
SCHEMBL3531493 0.71 SMN1; SMN2 (0.33)
Iodide SCHEMBL8592940 0.69 CTDSP1 (0.37)
SCHEMBL739514 0.69 PABPC1 (0.45) ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3698629-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2020-08-26 EP claimed
EP-3695721-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2020-08-19 EP claimed
EP-3155091-B1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES BIOMATRICA INC (US) 2020-04-08 EP claimed
EP-1264212-B1 ELEMENTS FOR FORMING PRINT-OUT IMAGES DU PONT (US) 2009-02-18 EP claimed
CN-115768351-A Fluid characterization method 新生代吉恩公司 2023-03-07 CN disclosed
US-20230017064-A1 METHODS FOR THE CHARACTERIZATION OF FLUID NEXTGEN JANE, INC. 2023-01-19 US disclosed
US-20220396836-A1 METHODS AND SYSTEMS FOR MENSTRUALOME ANALYSIS NEXTGEN JANE, INC. 2022-12-15 US disclosed
CN-115066207-A Method and system for menses group analysis 新生代吉恩公司 2022-09-16 CN disclosed
EP-4051109-A1 METHODS FOR THE CHARACTERIZATION OF FLUID NextGen Jane, Inc. (US) 2022-09-07 EP disclosed
EP-4051127-A1 METHODS AND SYSTEMS FOR MENSTRUALOME ANALYSIS NextGen Jane, Inc. (US) 2022-09-07 EP disclosed
EP-3155395-B1 METHODS AND COMPOSITIONS FOR STABILIZATION OF NUCLEIC ACIDS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES BIOMATRICA INC (US) 2021-06-02 EP disclosed
WO-2021087374-A1 METHODS FOR THE CHARACTERIZATION OF FLUID NEXTGEN JANE, INC. (US) 2021-05-06 WO disclosed
US-20210000103-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES BIOMATRICA, INC. 2021-01-07 US disclosed
EP-3698629-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2020-08-26 EP disclosed
EP-3695721-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2020-08-19 EP disclosed
EP-3155091-B1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES BIOMATRICA INC (US) 2020-04-08 EP disclosed
US-20170202211-A1 Stabilization of Metabolically-Active Cells in a Blood Sample at Ambient Temperatures EXACT SCIENCES CORPORATION 2017-07-20 US disclosed
US-20170198335-A1 Stabilization of Non-Denatured Polypeptides, Nucleic Acids, and Exosomes in a Blood Sample at Ambient Temperatures BIOMATRICA, INC. (US) 2017-07-13 US disclosed
EP-3155091-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES Biomatrica, INC. (US) 2017-04-19 EP disclosed
WO-2015191634-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES BIOMATRICA, INC. (US) 2015-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170202211-A1 Stabilization of Metabolically-Active Cells in a Blood Sample at Ambient Temperatures G6PD, PCK2, PCK1 MEN1 496/4885ALDH1A1 409/4885KMT2A 2163/4885
US-20170198335-A1 Stabilization of Non-Denatured Polypeptides, Nucleic Acids, and Exosomes in a Blood Sample at Ambient Temperatures EXOSC5, EXOSC9, EXOSC10 MEN1 2416/4885ALDH1A1 3966/4885KMT2A 3779/4885
US-20210000103-A1 STABILIZATION OF METABOLICALLY-ACTIVE CELLS IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES G6PD, PCK2, PCK1 MEN1 496/4885ALDH1A1 409/4885KMT2A 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.